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Background: This randomized Phase III trial will evaluate whether the methylene blue-assisted technique is efficient
for harvesting lymph nodes after radical surgery for gastric cancer.
Methods/design: Patients that undergo distal or total gastrectomy with radical nodal dissection will be randomly
assigned to Group A: the standard group, the lymph nodes (LNs) will be harvested from the fresh specimen
immediately after surgery, or Group B: the methylene blue-assisted group, where the LNs will be harvested from
specimens fixed with 10% buffered formalin with methylene blue for 48 hours after surgery. The primary endpoint
is the ratio of the number of the harvested LNs per time (minute). The secondary endpoint is the number of harvested
LNs. A 25% reduction in the ratio of harvested lymph-node/time (minute) was determined to be necessary for this test
treatment, considering the balance between the cost and benefit. Retrospective data was used to estimate the ratio of
the number of the harvested LNs per time (minute) to be 40/30 minutes in Group A. A 25% risk reduction and a rate of
40/22.5 minutes is expected in Group B. Therefore, the sample size required ensuring a two-sided alpha error of 5%
and statistical power of 80% is 52 patients, with 26 patients per arm. The number of patients to be accrued was set at
60 in total, due to the likelihood of enrolling ineligible patients.
Trial registration: UMIN000008624
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Gastric cancer is the second most frequent cancer-related
cause of death after lung cancer [1]. Surgical resection
with radical lymphadenectomy is a standard treatment
when gastric cancer is a local disease. Treatment strategy
is determined based on the pathological diagnoses of
tumor invasion and lymph-node metastasis. When deter-
mining N factor, TNM classification recommends nodal
examination at least 16 or more regional lymph nodes
(LNs) [2].
Nodal sampling from the specimens could be affected
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reproduction in any medium, provided the orgastrectomy, and the method for harvesting LNs. Sur-
geons harvest LNs from the fresh specimens immedi-
ately after surgery in Japan, while the pathologists from
the specimens fixed with formalin after surgery in other
countries [3]. Although surgeons may be more enthusi-
astic for harvesting LNs than pathologists, it must be
tough to do such work just after surgery. On the other
hand, nodal sampling may be difficult for pathologists
who are not familiar with surgical anatomy. Moreover,
the tissues fixed by formalin are hard and difficult to
be separated; by which nodal sampling must be time-
consuming work for most pathologists.
Methylene blue-assisted technique is another approach
for harvesting LNs. The specimens are fixed with forma-
lin with methylene blue after surgery, by which physi-
cians are easy to pick up LNs stained by blue dye.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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that the methylene blue-assisted technique was signifi-
cantly superior than the conventional methods in the
number of and the time for harvesting LNs when the
samples were fixed with formalin [4]. In gastric cancer, a
few Japanese surgeons reported efficacy of this method
in single arm studies [5,6]. It remains unclear whether
the methylene blue-assisted technique is superior to
standard method using the fresh samples.
Based on these, we conducted a randomized phase III
study to confirm the superiority of the methylene blue-
assisted technique compared with the standard approach
using the fresh sample in harvesting LNs by surgeons




The purpose of the study is to confirm the efficiency of
the methylene blue-assisted technique in comparison to
the standard approach using fresh samples for harvest-
ing LNs by surgeons after gastrectomy with radical
lymphadenectomy for gastric cancer.
Study setting and protocol review
The study is an open-label, randomized Phase III trial.
The protocol has been approved by the Institutional Re-
view Committee of Kanagawa Cancer Center.
Resources
Research grants are from the Kanagawa Standard Anti-
cancer Therapy Support System (non-profit organization
KSATTS).
Endpoints
The primary endpoint is the ratio of the number of the
harvested LNs per time (minute). The secondary end-
point is the number of harvested LNs. We set the ratio
of the number of the harvested LNs per time (minute)
as the primary endpoint because this is a measure for
the efficacy; however, the stage migration is a measure
for the accuracy not for the efficacy. Theoretically, the
test arm has a superior in the efficacy but the same ac-
curacy as compared with the control arm. To guarantee
this, we set the stage migration as a secondary endpoint.
Eligibility criteria
The tumors will be staged according to Japanese classifi-
cation of gastric carcinoma 3rd English edition [7]. The
inclusion criteria are:
(i). Histologically proven adenocarcinoma of the
stomach.
(ii).Clinical stage 1–3 disease.(iii). R0 resection is achieved by gastrectomy with D1+
or D2 lymphadenectomy according to Japanese
gastric cancer treatment guidelines 2010 (ver. 3) as a
primary treatment [8].
The patients that receive any other treatment before
surgery will be excluded.
All participants gave written informed consent before
study entry.
Registration
Surgeons will register the eligibility criteria to the data
center after confirmation during the surgery. The pa-
tients will be randomized and assigned to the standard
group and the methylene blue-assisted group by a cen-
tralized dynamic method using the following factors:
lymphadenectomy (D1+/D2), type of gastrectomy (sub-
total/total), and surgical experience (less than 15 years/
15 years-). The accrual was started in August 2012 and
is to continue for 1 year.
Qualification of the participating surgeons
All surgeons have previous experience in harvesting LNs
from more than 50 specimens.
Methods
Patients with gastric cancer will undergo distal or total gas-
trectomy with radical lymphadenectomy. The extent of dis-
section will principally follow the third edition of the Gastric
Cancer Treatment Guideline published by the Japanese
Gastric Cancer Association [6]. Spleen-preserving D2
total gastrectomy is permitted in this study. The LNs
will be harvested from the specimen immediately after
surgery in the standard group. The specimens will be
fixed with 10% buffered formalin with methylene blue
in the methylene blue-assisted group, and the LNs will
be harvested from the specimens. In this study, the
concentration of the formalin is 10% in both arms.
More, the concentration of the formalin is standard-
ized throughout the study. All specimens were then
fixed in 10 percent buffered formalin over two nights.
LN harvesting in both arms are done by surgeons. The
time for harvesting LNs is defined as that from the ini-
tiation to the termination. The ratio of the number of
the harvested LNs per time (minute) is calculated.
Statistical methods
The present study is a randomized phase III study to
evaluate the efficiency of the methylene blue-assisted
lymph node technique for harvesting LNs after surgery
for gastric cancer. The primary endpoint is the ratio of
the number of the harvested LNs per time (minute). A
25% reduction in the ratio of harvested lymph-node/
time (minute) is necessary for this test treatment,
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Retrospective data from this institution was used to es-
timate the ratio of the number of the harvested LNs
per time (minute) to be 40/30 minutes in the control
arm. A 25% risk reduction in the test arm is expected,
with a rate of 40/22.5 minutes in the test arm. This
situation, will require a sample size of 52 patients, with
26 patients per arm to ensure a two-sided alpha error
of 5% and statistical power of 80%. A total of 60 patients
will be accrued due to the likelihood of enrolling ineligible
patients.
The primary end point of the study is analyzed in the
intent-to-treat (ITT) population using a Wilcoxon rank-
sum test. The secondary endpoints, number of harvest
lymph node and time of harvested lymph nodes are
similarly analyzed using a Wilcoxon rank-sum test.
Multivariate analysis is also used to analyze those end-
points with adjustment for clinically important back-
ground factors.
Discussion
According to the results of the JCOG9501 trial, which
was a Japanese multicenter phase III study to compare
D2 and D2 plus para-aortic dissection for gastric cancer
surgery, the median number of harvested LNs was 54
(range: 14–161) in the D2 group and 74 (range: 30–235)
in the extended para-aortic dissection group [9]. In this
trial, the experienced surgeons harvested LNs from the
fresh specimens immediately after surgery. These data
suggested that the number of harvested LNs tended to
be much higher for extended dissection than normal D2,
but that there was a wide variation even in D2 dissec-
tion. The first possible reason for this wide variation is
that the number of LNs is different in each patient.
However, no literature supports this possibility. The sec-
ond possible reason is the difference in the gastrectomy
type. The extent of nodal dissection was limited in the
distal D2 gastrectomy compared with total D2 gastrec-
tomy. The third possible difference is the skill of the sur-
geon for harvesting the LNs. In the present trial, we set
the type of gastrectomy, extent of lymph node dissec-
tion, and surgeon’s experience as the stratification fac-
tors. Therefore, we will be able to minimize these effects
regarding the differences in the standard method and
methylene blue-assisted technique.
The hypothesis of the present study is that the methy-
lene blue-assisted technique is superior to the conven-
tional method, and is associated with a 25% reduction in
the ratio of harvested lymph nodes/time (minutes). In
general, the statistical hypothesis is determined by con-
sidering the balance between the risks and benefits of
the standard arm and the test arm. However, there is no
risk associated with the methylene blue-assisted technique
for the patients. Therefore, it is possible to conclude thatthe methylene blue-assisted technique is effective even
when the difference in the ratio of harvested lymph
nodes/time is very small. However, it is not practical to
statistically prove the significance of small differences.
Considering the practical and acceptable sample sizes
based on the previous data, we determined our statistical
hypothesis.
In this trial, the primary endpoint is the ratio of the
number of harvested LNs per time period (minutes).
Our goal is to evaluate the efficacy of harvesting LNs by
surgeons. On the other hand, the difference in the num-
ber of harvested LNs could produce stage migration be-
tween the two groups even though the number of nodal
examinations was more than 16 in each group. There-
fore, an expletory analysis is needed to evaluate the stage
migration and cancer survival in the two groups.
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